CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Medicine for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

December 5, 2017

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that Dr. Bill Lundberg, Chief Scientific Officer of CRISPR, is scheduled to present new data on CTX001, an investigational CRISPR gene-edited therapy for patients suffering from β-thalassemia and sickle cell disease at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 10th, 2017.

Session: 112 Thalassemia and Globin Gene Regulation I Track

Time and Date: Sunday, December 10, 2017: 7:45 AM

Location: Georgia World Congress Center, Building B, Level 2, B213-B214

Presentation: CRISPR/Cas9 Genome Editing to Treat Sickle Cell Disease and B-Thalassemia: Re-Creating Genetic Variants to Upregulate Fetal Hemoglobin Appear Well-Tolerated, Effective and Durable

Presenter: Bill Lundberg, MD, Chief Scientific Officer of CIRSPR Therapeutics

About CTX001

CTX001 is an investigational CRISPR gene-edited therapy for patients suffering from β-thalassemia and sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high level of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is a form of the oxygen carrying hemoglobin that is naturally present at birth and is normally replaced by the adult form of hemoglobin. The elevation of HbF is expected to alleviate transfusion-requirements for β-thalassemia patients and painful and debilitating sickle crises for sickle cell patients.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts. For more information, please visit http://www.crisprtx.com.

CONTACTS

CRISPR Therapeutics

Investors:
Chris Erdman
617-307-7227
Chris.erdman@crisprtx.com
or
Chris Brinzey
Westwicke Partners
339-970-2843
chris.brinzey@westwicke.com
or
Media:
Jennifer Paganelli
WCG for CRISPR
347-658-8290
jpaganelli@wcgworld.com

CRISPR Therapeutics AG